SRC and osteosarcoma: In conclusion, through a combination of systemic pharmacology, molecular docking and experimental validation, this study provides powerful proof that daidzein has little negative effect on normal cells and exerts an antitumor effect through the Src-ERK axis, which suggests that daidzein could act as a potential osteosarcoma chemotherapy agent.